Dr. Dino Prado of Envita Medical Centers shares results from a 2024 study showing their precision targeting and immunotherapy approach achieved 35-fold higher response rates and 43-fold higher quality-of-life scores than conventional oncology.
This is Dr. Dino Prado, founder of Envita Medical Centers. I want to personally thank you for your referrals and your trust in our cancer work. I'm proud to report that our 2024 published study showed 35 times better responses than conventional standard oncology and even more important, 43 times better quality of life. The work of in Vita's precision targeting and immunotherapy made all the difference in the world. If you need our help, Visit us@invita.com envite.com.
